Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lexaria Bioscience ( (LEXX) ) has shared an update.
Lexaria Bioscience has announced promising results from a study on its DehydraTECH-processed semaglutide, showing improved brain biodistribution compared to conventional formulations. This advancement could enhance the safety and efficacy of GLP-1 drugs, which are crucial for regulating body weight and appetite through brain neurochemistry, potentially leading to more effective treatments with fewer side effects.
The most recent analyst rating on (LEXX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing on enhancing the delivery and efficacy of pharmaceutical compounds through its proprietary DehydraTECH technology.
Average Trading Volume: 174,140
Technical Sentiment Signal: Sell
Current Market Cap: $23.67M
Learn more about LEXX stock on TipRanks’ Stock Analysis page.